Andy Jassy, Amazon CEO (Isaac Brekken/AP Images for NFL, File)

Ama­zon joins Fred Hutch on clin­i­cal tri­al for per­son­al­ized can­cer vac­cine — re­port

Ama­zon is part­ner­ing with the Fred Hutchin­son Can­cer Re­search Cen­ter on a Phase I tri­al for a can­cer vac­cine tar­get­ing metasta­t­ic melanoma and breast can­cer.

The clin­i­cal tri­al is part of Ama­zon’s Grand Chal­lenge, a se­cre­tive lab the tech gi­ant start­ed in 2014 to work on can­cer re­search among a num­ber of oth­er ef­forts, and was first re­port­ed in Busi­ness In­sid­er. Ac­cord­ing to clin­i­cal­tri­als.gov, the Phase I tri­al will test a tu­mor anti­gen vac­cine ther­a­py along­side nivolum­ab (Op­di­vo) in pa­tients with metasta­t­ic and re­frac­to­ry late stage melanoma and HR+/HER2- breast can­cer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.